Alternatives to BC Platforms

Labguru, a cloud-based Electronic Lab Notebook, LIMS and Informatics Platform that offers a complete solution to life science research and industry, is secure and reliable. It records and manages laboratory data, inventory, molecular biology tools, and chemistry tools. This allows labs to run more efficiently and automates lab operations. Labguru allows scientists to design experiments and workflows. They can also capture structured and unstructured information, manage projects, and share their results. You can create custom-designed experiment templates and integrate protocols, SOPs and other cutting-edge features to improve data quality, streamline workflows, and reduce costs. Labguru is available via the cloud on desktops as well as mobile devices. Labguru is part Holtzbrinck Publishing Group. It serves more than 100,000 scientists from universities, research institutes, startups, and large pharma companies around the world.

SYNTHIA™ Retrosynthesis software, developed by computer scientists and coded by chemists, allows scientists to quickly and easily navigate novel and innovative pathways for novel and previously published target molecules. You can quickly and efficiently scan hundreds pathways to identify the best options for your needs. Discover the most cost-effective route to your target molecule with the latest visualization and filtering features. You can easily customize the search parameters to eliminate or highlight reactions, reagents, or classes of molecules. Explore innovative and unique syntheses to build your desired molecule. Easy to generate a list for starting materials that are commercially available for your synthesis. ISO/IEC 27001 Information Security Certification will guarantee the confidentiality, integrity and protection of your data.

Scitara DLX™ provides a swift connectivity framework suitable for any instrument found within life science laboratories, all while operating on a cloud-based platform that is both compliant and auditable. As a versatile digital data infrastructure, Scitara DLX™ facilitates connections between various instruments, resources, applications, and software utilized in the lab. The comprehensive cloud system ensures that all data sources are interconnected, promoting seamless data movement across numerous endpoints. Consequently, researchers can concentrate on their scientific endeavors instead of being bogged down by data-related challenges. Moreover, DLX intelligently curates and corrects data as it is processed, fostering the creation of accurate and well-organized data models that are essential for enhancing AI and ML systems. This robust approach plays a vital role in advancing digital transformation strategies within the pharmaceutical and biopharmaceutical sectors. By unlocking valuable insights from scientific data, the platform accelerates decision-making processes in drug discovery and development, ultimately aiding in the expedited launch of new medications into the market. Additionally, the integration of such a sophisticated infrastructure not only streamlines workflows but also enhances collaboration among researchers, paving the way for innovative solutions in the life sciences field.

Unlike most data management systems, PHEMI Health DataLab is built with Privacy-by-Design principles, not as an add-on. This means privacy and data governance are built-in from the ground up, providing you with distinct advantages: Lets analysts work with data without breaching privacy guidelines Includes a comprehensive, extensible library of de-identification algorithms to hide, mask, truncate, group, and anonymize data. Creates dataset-specific or system-wide pseudonyms enabling linking and sharing of data without risking data leakage. Collects audit logs concerning not only what changes were made to the PHEMI system, but also data access patterns. Automatically generates human and machine-readable de- identification reports to meet your enterprise governance risk and compliance guidelines. Rather than a policy per data access point, PHEMI gives you the advantage of one central policy for all access patterns, whether Spark, ODBC, REST, export, and more

Scispot delivers a powerful lab informatics platform that transforms how life science labs operate. Through its configurable LabOS™ ecosystem, teams can select from a unified suite of tools covering ELN, LIMS, SDMS, QMS, and AI capabilities—all accessible through an intuitive no-code interface. Purpose-built for CROs, Diagnostic Labs, and Biotech R&D teams, Scispot addresses critical challenges in Sample Management, Freezer Management, and GxP Compliance. The platform seamlessly connects with 200+ lab instruments and 7,000+ applications, eliminating manual data entry while ensuring regulatory adherence. Scispot's AI-powered analytics convert experimental data into actionable insights, accelerating discovery timelines. With rapid implementation and a focus on user experience, Scispot enables 1000+ lab scientists and operators to standardize processes, maintain compliance, and focus resources on innovation rather than administrative overhead.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. More than 2 million scientists and 10,000 customers trust Dotmatics to accelerate research and help make the world a healthier, cleaner, and safer place to live.

Eidogen-Sertanty's Target Informatics Platform (TIP) stands out as the pioneering structural informatics system and knowledgebase that empowers researchers to explore the druggable genome through a structural lens. By harnessing the burgeoning wealth of experimental protein structure data, TIP revolutionizes structure-based drug discovery, shifting it from a limited, low-throughput field to a dynamic and data-rich scientific discipline. It is specifically designed to connect the realms of bioinformatics and cheminformatics, providing drug discovery scientists with a repository of insights that are not only unique but also highly synergistic with the information available from traditional bio- and cheminformatics tools. The platform's innovative combination of structural data management with advanced target-to-lead calculation and analytical capabilities significantly enhances every phase of the drug discovery process. With TIP, researchers are better equipped to navigate the complexities of drug development and make informed decisions.

Revolutionize the fields of drug discovery and materials research through cutting-edge molecular modeling techniques. Our computational platform, grounded in physics, combines unique solutions for predictive modeling, data analysis, and collaboration, facilitating swift navigation of chemical space. This innovative platform is employed by leading industries globally, serving both drug discovery initiatives and materials science applications across various sectors including aerospace, energy, semiconductors, and electronic displays. It drives our internal drug discovery projects, overseeing processes from target identification through hit discovery and lead optimization. Additionally, it enhances our collaborative research efforts aimed at creating groundbreaking medicines to address significant public health challenges. With a dedicated team of over 150 Ph.D. scientists, we commit substantial resources to research and development. Our contributions to the scientific community include more than 400 peer-reviewed publications that validate the efficacy of our physics-based methodologies, and we remain at the forefront of advancing computational modeling techniques. We are steadfast in our mission to innovate and expand the possibilities within our field.

Cytel stands out as a prominent global innovator in software for clinical trial design, biometrics, and advanced analytics, focusing on maximizing the efficiency of clinical trials while aiding pharmaceutical companies in harnessing the full scope of both clinical and real-world data. Established in 1987 by renowned statisticians Cyrus Mehta and Nitin Patel, Cytel has consistently been a leader in adaptive clinical trial technology and the field of biostatistics. Its software solutions, notably the East Horizon platform, facilitate accurate trial design and simulation, employing adaptive and Bayesian methodologies to enhance protocols and expedite the drug development process. The East Horizon platform serves as a comprehensive integration of Cytel's reliable software offerings, featuring R integration that significantly improves trial design functions. Furthermore, Cytel provides the Xact software suite, which is an all-encompassing toolkit designed for statistical analysis of small datasets, including those with sparse and missing data. By continuously innovating and expanding its product offerings, Cytel remains committed to providing cutting-edge solutions that meet the evolving needs of clinical research.

Introducing IDBS Polar, the pioneering BioPharma Lifecycle Management (BPLM) platform that streamlines tedious manual operations, empowering you to carry out processes more effectively while gathering the essential data needed to speed up market entry by addressing significant hurdles in process design, optimization, scale-up, and technology transfer. This innovative platform features interactive data analytics tools, including a bioreactor comparison tool tailored for biopharma development scientists. IDBS Polar excels at securely overseeing drug progression through comprehensive workflows, seamless integration, and insightful data analysis. Its structured workflows are crafted to ease the complexities of the BioPharma Lifecycle, ensuring process-aware planning, design, and execution of complete bioprocess and analytical unit operations. Meaningful integrations enhance the relevance of your data, while rapid incorporation into your development ecosystem fosters automation and establishes a robust, process-centric data framework. In an industry where precision and efficiency are paramount, IDBS Polar stands out as a vital solution for modern biopharmaceutical development.

Harnessing actionable insights from the leading AI-driven clinical analytics platform allows your teams to effectively manage risk and enhance performance throughout studies, systems, sites, and vendor relationships. The cutting-edge technology from Saama is specifically crafted to optimize workflows, automate labor-intensive tasks, and foster improved collaboration among various clinical functions such as operations, medical review, data management, biostatistics, and pharmacovigilance. Both sponsors and CROs depend on Saama's capabilities for data aggregation and AI solutions, which facilitate superior decision-making, minimize delays, and drastically reduce costs and timelines associated with drug development. By leveraging Saama's tools, you can accelerate the pace of clinical trial innovation. When your clinical data is centralized and continuously updated, it simplifies the lives of your ClinOps and medical review teams considerably. Furthermore, Data Managers, often undervalued, can shift their focus from repetitive tasks to the critical data points that truly drive project success, ensuring that their expertise is fully utilized in the process. This transformation not only enhances efficiency but also contributes to the overall quality of clinical outcomes.

Sapio Sciences delivers a cutting-edge AI-driven lab informatics platform that integrates Laboratory Information Management Systems (LIMS), Electronic Lab Notebooks (ELN), and a Scientific Data Cloud into one seamless ecosystem. It is tailored to advance scientific research, clinical diagnostics, drug discovery, and manufacturing through configurable, no-code solutions. The Sapio LIMS® automates complex workflows with full configurability, removing the need for programming. Sapio ELN® offers a flexible, adaptable electronic lab notebook that supports diverse experimental needs. The platform’s Scientific Data Cloud consolidates instrument and research data enterprise-wide, paving the way for AI-driven insights. By unifying these components, Sapio simplifies data management and boosts productivity across the lab lifecycle. The platform is accessible for a wide range of industries and research applications. It aims to reduce administrative burden and enhance collaboration within scientific teams.

Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.

DNAnexus Apollo™ enhances the efficiency of precision drug discovery by fostering collaboration that extracts valuable insights from omics data. The process of precision drug discovery involves the aggregation and examination of vast amounts of omics and clinical information. These extensive datasets serve as valuable assets; however, many traditional and custom-built informatics tools struggle to manage their intricacies and scale. Additionally, the effectiveness of precision medicine initiatives can be hindered by fragmented data sources, inadequate collaboration tools, and the challenges posed by complex, evolving regulatory and security demands. By enabling scientists and clinicians to jointly investigate and interpret omics and clinical data within a unified framework, DNAnexus Apollo™ bolsters precision drug discovery efforts. This platform, which is powered by a resilient and scalable cloud infrastructure, facilitates the seamless and secure sharing of data, tools, and analyses among peers and collaborators, regardless of whether they are nearby or across the globe. Ultimately, Apollo not only streamlines the data-sharing process but also enhances the overall collaborative experience in the pursuit of innovative drug discoveries.

3decision® serves as a cloud-based repository for protein structures, focusing on efficient management of structural data and offering sophisticated analytics to support teams involved in the discovery of small molecules and biologics, thereby expediting the process of structure-based drug design. The platform consolidates and standardizes both experimental and computational protein structures sourced from publicly available databases such as RCSB PDB and AlphaFoldDB, in addition to proprietary datasets, and accommodates formats like PDBx/mmCIF and ModelCIF. This comprehensive approach guarantees seamless access to a variety of structural formats including X-Ray, NMR, cryo-EM, and modeled structures, thereby promoting collaboration and bolstering research initiatives. In addition to its storage capabilities, 3decision® enhances each entry with valuable metadata and sequence information, which encompasses details on protein-ligand interactions, antibody annotations, and specifics about binding sites. Equipped with advanced analytical instruments, the platform is capable of pinpointing druggable sites, evaluating off-target risks, and facilitating comparisons of binding sites, which collectively transform extensive structural datasets into practical insights that can drive research forward. Furthermore, its cloud-based architecture fosters enhanced collaboration among research teams, making it easier for scientists to share findings and insights, ultimately leading to more innovative approaches in drug discovery and development.

Harnessing RNA sequencing (RNA-seq) data alongside Artificial Intelligence presents both a crucial necessity and a significant opportunity for creating therapies aimed at correcting splicing errors. By leveraging machine learning, we can uncover novel splicing errors and swiftly formulate therapeutic compounds to address them. Our AI platform, SpliceCore, is specifically designed for discovering RNA therapeutics. This cutting-edge technology focuses on analyzing RNA sequencing data with unparalleled efficiency. It can swiftly identify, evaluate, and validate potential drug targets, outpacing traditional methodologies. Central to SpliceCore is our unique repository containing over 5 million potential RNA splicing errors, making it the largest of its kind globally and instrumental for testing any RNA sequencing dataset submitted for analysis. The integration of scalable cloud computing allows us to handle vast quantities of RNA sequencing data in a way that is not only efficient but also cost-effective, significantly speeding up the pace of therapeutic advancements. This innovative approach promises to revolutionize the landscape of RNA therapeutics.

The L7 Enterprise Science Platform (L7|ESP®) is a comprehensive platform designed to contextualize data and remove business silos through process orchestration. This all-in-one solution supports the digitalization of data and scientific processes within life sciences organizations. It includes native applications like L7 LIMS, L7 Notebooks, L7 MES, and L7 Scheduling. L7|ESP seamlessly integrates with third-party applications, lab instruments, and devices to consolidate all data into a unified model. Featuring a low-code/no-code workflow designer and numerous pre-built connectors, it ensures rapid implementation and full automation. Utilizing a single data model, L7|ESP enhances advanced bioinformatics, AI, and ML to provide new scientific and operational insights. L7|ESP addresses the data and lab management needs and challenges within the life sciences sector, specifically targeting: ● Research and Diagnostics ● Pharma and CDMO ● Clinical Sample Management Explore the L7 Resource Center for on-demand recordings, case studies, datasheets, and more: l7informatics dot com/resource-center

AQBioSim is an innovative cloud-based platform created by SandboxAQ that utilizes Large Quantitative Models (LQMs) based on principles of physics and chemistry to transform the processes of material discovery and optimization. By combining techniques such as Density Functional Theory (DFT), Iterative Full Configuration Interaction (iFCI), Generative AI, Bayesian Optimization, and Chemical Foundation Models, AQBioSim facilitates highly accurate simulations of molecular and material behaviors in real-world scenarios. Among its numerous features, AQBioSim can predict performance under various stressors, enhance formulation processes through in silico testing, and investigate eco-friendly chemical methods. A standout achievement of AQBioSim lies in its remarkable progress in battery technology, where it has cut the time needed for lithium-ion battery end-of-life predictions by an astonishing 95%, while also attaining 35 times greater accuracy using only 50 times less data. This platform thus not only accelerates material innovation but also significantly contributes to advancements in sustainable energy solutions.

NuVerve is a collaborative SaaS that offers Scientific Data Intelligence for scientists. It provides a set easy-to-use features to structure data, create custom analyses, and automatically generate reports. NuVerve, priced at $75/month, is available to all scientists.

The Sapio Scientific Data Cloud is an innovative scientific data management platform that intelligently consolidates and contextualizes laboratory data, assay outcomes, instrument outputs, archives, and external ELN/LIMS records into a cohesive, searchable interface that requires no programming skills. This system facilitates automated data acquisition and interpretation from more than 200 instrument adaptors, employs semantic search capabilities driven by ontological frameworks, and features integrated charting along with sophisticated neural-network analytics such as ANOVA, best-response curves, and flow-cytometry gating. Furthermore, it delivers AI-generated insights to enhance research efficiency. To ensure the protection of sensitive information, it offers secure, role-based access and comprehensive data archiving solutions, while providing interactive viewers for proteins, molecules, plasmids, and system-wide analyses that empower scientists to delve into their findings. Additionally, the seamless integration with Sapio LIMS and ELN systems ensures that data is automatically linked with relevant samples, experiments, and entities for streamlined research workflows. This powerful combination of features makes the Sapio Scientific Data Cloud an essential tool for modern laboratories.

At Metabolon, we proudly provide the most extensive Level 1 library in the metabolomics field. Our unique library has been meticulously developed and refined over two decades, boasting more than 5,400 entries. The majority of these entries are classified as Level 1, comprising roughly 85% (around 4,600 entries); however, about 15% of the library consists of Level 2 entries (approximately 800 entries), which are categorized as such due to the unavailability of commercial standards necessary for Level 1 classification. Thanks to our unparalleled library size and exceptional annotation confidence, Metabolon offers precise and highly actionable insights tailored to our clients’ scientific or clinical needs. The applications of metabolomics span a broad spectrum of research areas, including soil health, nutritional studies, preclinical investigations, and clinical trials. Whether you're identifying trends within a population or fine-tuning an individual's treatment plan, metabolomics serves as a powerful tool to uncover crucial answers to pressing questions in various fields. With such extensive resources at your disposal, the potential for discovery is truly limitless.

LabSolutions LC/GC is designed to enhance software functionality by allowing the simultaneous control and analysis of up to four LC/GC systems, thereby creating a more intuitive user experience. Complementing this, LabSolutions DB is a SQL-driven platform that merges data management capabilities with LabSolutions LC/GC while adhering to ER/ES Regulations. It is noteworthy that not only Shimadzu equipment but also HPLCs and GCs from other manufacturers can be managed through this system. Since all analytical information is stored in the database on a server, LabSolutions CS allows for data access from any networked personal computer, enhancing versatility. Moreover, it facilitates instrument monitoring and control from client PCs that are not directly connected to the analytical devices. Additionally, LabSolutions CS supports Citrix XenApp, enabling sophisticated server management capabilities. Beyond just Shimadzu chromatography and LC-MS/MS systems, LabSolutions C/S also allows for the integration and management of data from spectroscopy instruments and HPLCs and GCs made by other vendors, ensuring a comprehensive data management solution. This level of integration makes LabSolutions an essential tool for laboratories seeking efficiency and compatibility across various analytical platforms.

Rare diseases often lack comprehensive research, resulting in insufficient knowledge about essential elements for an effective drug discovery initiative. Our innovative AI platform, Healnet, addresses these issues by scrutinizing vast amounts of drug and disease data to uncover new connections that may lead to potential treatments. Utilizing cutting-edge technologies throughout the discovery and development process allows us to operate multiple phases simultaneously and on a large scale. The conventional approach of focusing on a single disease, target, and drug is overly simplistic, yet it remains the standard for most pharmaceutical companies. The future of drug discovery is driven by AI, characterized by parallel processes and an absence of rigid hypotheses, fundamentally integrating the three core paradigms of drug discovery into a cohesive strategy. This new paradigm not only enhances efficiency but also fosters creativity in developing solutions for complex health challenges.

Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.

Clara provides specialized tools and pre-trained AI models that are driving significant advancements across various sectors, such as healthcare technologies, medical imaging, pharmaceutical development, and genomic research. Delve into the comprehensive process of developing and implementing medical devices through the Holoscan platform. Create containerized AI applications using the Holoscan SDK in conjunction with MONAI, and enhance deployment efficiency in next-gen AI devices utilizing the NVIDIA IGX developer kits. Moreover, the NVIDIA Holoscan SDK is equipped with acceleration libraries tailored for healthcare, alongside pre-trained AI models and sample applications designed for computational medical devices. This combination of resources fosters innovation and efficiency, positioning developers to tackle complex challenges in the medical field.

The Kanteron Platform assimilated a wide array of medical images, digital pathology slides, genomic sequences, and patient information from various modalities, scanners, sequencers, and databases, delivering a comprehensive data toolkit to all teams within hospital networks. It emphasizes pharmacogenomics to avert adverse medication events and facilitates the application of precision medicine at the point of care by integrating data sources on drug-gene interactions that were formerly only accessible in less user-friendly formats, such as tables found in PDF documents. By incorporating major pharmacogenomic databases like PharmGKB, CGI, DGIdb, and OpenTargets, it enables users to customize their queries according to specific gene families, types of interactions, and drug classifications. Additionally, its adaptable AI allows users to select the dataset that best aligns with their specific use case, applying it effectively to pertinent medical images. This robust functionality not only enhances the accuracy of medical insights but also fosters a more personalized approach to patient care.

We are a biotechnology firm in the clinical stage, dedicated to unraveling biological complexities through the integration of cutting-edge innovations spanning biology, chemistry, automation, machine learning, and engineering, all aimed at revolutionizing drug discovery. Our approach allows for enhanced precision in biological manipulation with advanced techniques like CRISPR genome editing and synthetic biology. We also achieve reliable automation for intricate laboratory processes at an unprecedented scale through the use of sophisticated robotics. By employing neural network architectures, we conduct iterative analyses and draw insights from extensive, intricate datasets generated in-house. Furthermore, we are boosting the adaptability of high-performance computing capabilities through cloud-based solutions. Our initiative harnesses new technologies to foster continuous learning cycles around our datasets, establishing us as a next-generation biopharmaceutical enterprise. This is achieved through a harmonious integration of hardware, software, and data, all dedicated to the industrialization of drug discovery. We are transforming the conventional drug discovery pipeline and boast one of the most extensive, diverse, and in-depth pipelines among technology-driven drug discovery companies. Ultimately, our mission is to enhance the efficiency and effectiveness of drug development, paving the way for breakthrough therapies.

AI-powered drug discovery is a proven technology. Cerella extracts hidden insights from your drug discovery data to reveal the best compounds and most valuable experiment for your project. It can make confident predictions by accurately filling in the missing values. This is especially useful for expensive downstream experiments, which are impossible to predict using other methods. This allows you to do more with sparse and limited data sets.

Uncover biological markers, generate insights into the mechanisms of disease, identify novel pharmaceuticals, or detect variations in protein concentrations through a meticulously structured series of experiments. We have simplified the process of harnessing the potential of mass spectrometry and proteomics, enabling you to concentrate on the intricacies of biology and advance toward groundbreaking discoveries. Our automated and consistent workflow facilitates faster initiation and completion of experiments, granting you the authority and adaptability to make timely decisions. By prioritizing biological insights and fostering collaborative efforts, our scalable proteomics data processing system is designed for repeated use. We have delegated intensive and repetitive tasks to the cloud, ensuring a smooth and satisfying experience. Our sophisticated proteomics workflow effectively integrates numerous complex elements, allowing for the efficient analysis and processing of larger-scale experiments, ultimately enhancing the research journey. Thus, with our innovative approach, researchers can now delve deeper into the molecular landscape and achieve more significant breakthroughs than ever before.

BIOiSIMTM represents a groundbreaking 'virtual drug development engine' that significantly enhances the drug development sector by effectively identifying drug compounds that are most likely to provide meaningful therapeutic benefits for various diseases or conditions. We provide an array of translational solutions that are tailored to meet the specific needs of your pre-clinical and clinical initiatives. Central to our offerings is the highly validated BIOiSIMTM platform, which supports the development of small molecules, large molecules, and viruses. This innovative platform is underpinned by extensive data derived from thousands of compounds across seven different species, resulting in a level of robustness that is uncommon in the field. Emphasizing human health outcomes, the heart of the platform features a translatability engine that seamlessly converts insights gained from different species. Importantly, the BIOiSIMTM platform can be deployed prior to the initiation of preclinical animal trials, facilitating earlier insights and potentially reducing the costs associated with outsourced experimentation. By integrating these advanced capabilities, we aim to streamline the drug development process and accelerate the journey from discovery to market.

Prognos stands as the leading provider of specialized lab data, now enhanced by a comprehensive ecosystem of healthcare data assets tailored to address even the most intricate inquiries. Pioneering the market, Prognos established a seamless integration of various lab data types, unlocking their full analytical potential through a robust platform. Currently, this platform connects millions of medical and prescription claims, and its sources continue to expand daily. With access to billions of data points, users can explore harmonized lab data covering 325 million patients, alongside both open and closed medical claims as well as prescription claims. The Prognos Marketplace serves as a user-friendly healthcare data marketplace designed to streamline the data selection and contracting process, allowing users to easily curate and acquire the health data they require at their convenience. This innovative approach empowers businesses to begin with patient-centric data that aligns with their specific operational needs, ensuring they have the right information at their disposal to drive informed decisions. In this way, Prognos not only enhances data accessibility but also fosters a deeper understanding of healthcare dynamics.

Pluto was founded in 2021 by the Wyss Institute of Harvard University. It has been a trusted partner for many life sciences organizations across the country, from biotech start-ups and public biopharma companies. Our cloud-based platform allows scientists to manage all their data, run bioinformatics analysis, and create interactive visualizations that are published-quality. The platform is being used for a variety of biological applications. These include preclinical and translational science research, cell and gene therapies and drug discovery and development.

ZONTAL stands out as a prominent provider of digital solutions tailored for the life sciences sector, focusing on optimizing laboratory workflows and speeding up research results through advanced analytics and data science. Their all-encompassing platform features a range of products aimed at improving data management, including the Digital Lab for connecting experts and data, Data Preservation for the protection of critical information, and the Life Science Analytics Platform for seamless integration of analytics into laboratory processes. By prioritizing data to be Findable, Accessible, Interoperable, and Reusable (FAIR), ZONTAL enables organizations to reduce the complexities of data handling, conduct real-time analyses, and tap into limitless analytical capabilities. This transformation not only enhances laboratory operations but also promotes innovation within the modern digital landscape, ensuring that organizations remain competitive and forward-thinking in their research endeavors.

LiveDesign serves as an integrated informatics solution that empowers teams to accelerate their drug discovery initiatives through collaborative design, experimentation, analysis, tracking, and reporting on a unified platform. It allows for the collection of innovative ideas alongside experimental and modeling data seamlessly. Users can develop and archive new virtual compounds within a centralized repository, assess them with sophisticated models, and prioritize the most promising designs. By merging biological data and model outputs from various corporate databases, the platform leverages advanced cheminformatics to provide a comprehensive analysis of all information simultaneously, facilitating quicker compound development. The platform employs cutting-edge physics-based methodologies along with machine learning to enhance prediction accuracy significantly. Teams can collaborate in real-time, regardless of location, enabling them to share concepts, conduct tests, make revisions, and progress chemical series while maintaining a clear record of their work. This not only fosters innovation but also ensures that projects remain organized and efficient throughout the drug discovery process.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.

Discover valuable insights within your data by utilizing the Cortellis™ suite of life science intelligence tools, enabling you to make more informed decisions throughout the entire R&D process. We have alleviated the burden of gathering, integrating, and analyzing data, allowing you to concentrate on the essential choices necessary for expediting your products' market entry. With a unique combination of extensive, high-quality data, fortified by profound domain knowledge, industry insight, and therapeutic expertise, Cortellis reveals crucial insights that facilitate data-driven decisions, ultimately speeding up innovation. Access tailored, actionable responses to your specific inquiries throughout the R&D lifecycle, drawing from the most comprehensive and in-depth intelligence sources available. By incorporating Cortellis into your daily routine, you can significantly enhance the pace of innovation and streamline your workflow. This makes Cortellis not just a tool, but a vital partner in your path to success.

ScienceDesk's data automation simplifies the integration of artificial intelligence within the field of materials science. This tool serves as a practical solution for teams to consistently implement and utilize the latest AI algorithms in their daily workflows. It features customizable attributes, universal identifiers, QR codes, and a robust search engine that connects sample data with experimental results. As a groundbreaking platform, ScienceDesk facilitates collaboration among scientists and engineers, allowing them to engage with and glean insights from their experimental findings. However, the full potential of this resource remains untapped due to the diverse data formats and a reliance on specialists to manually retrieve targeted information. The ScienceDesk research data management system addresses this challenge by merging documentation with data analysis within a thoughtfully designed data structure. Our algorithms empower researchers and scientists, granting them comprehensive command over their data. They can not only exchange datasets but also share their analytical expertise, fostering a more collaborative research environment. Overall, ScienceDesk enhances data accessibility and encourages innovative approaches in scientific investigation.

Discngine Assay serves as a comprehensive laboratory informatics platform that unifies all stages of plate-based assays into a streamlined, compliant, and effective workflow, proving to be a vital resource for screening research laboratories. This platform empowers researchers to optimize their entire High Throughput Screening process, encompassing everything from managing samples and analyzing assay data to data storage and qualifying liquid handling instruments. With its user-friendly interface and powerful API, Discngine Assay integrates effortlessly with laboratory equipment and the existing IT infrastructure, facilitating effective data collection and processing. Tailored to expedite the discovery of new molecules, it meets the requirements of the pharmaceutical, biotech, and contract research organization sectors, thereby promoting collaboration and fostering innovation within life sciences research. Furthermore, its ability to adapt to various laboratory environments makes it a versatile solution for evolving research demands.

A cloud platform that is accessible from anywhere, infinitely scalable, and powered by AI offers collaborative features while adhering to the strictest security and compliance standards. This user-friendly software, designed by specialists in neuroimaging and data science, addresses the specific and complex requirements of the neuroscience field. Customized to suit your particular needs, it supports a wide range of activities, including research, clinical trials, point-of-care applications, algorithm development, and the utilization of brain-related data. The platform facilitates global data aggregation and consolidates imaging studies into a single cloud environment. It provides an efficient, comprehensive management solution for clinical, real-world data, and medical imaging information. Users receive tailored, expert assistance throughout their studies to ensure successful outcomes. Additionally, it features centralized reading capabilities and the option to compare quantitative results against a normative database. The platform also guarantees high-quality, shareable reporting and data export options to streamline the submission approval process, making it an invaluable tool for neuroscience professionals. Furthermore, its innovative design enhances collaboration among researchers and clinicians, fostering a community dedicated to advancing the field.

Uncountable assists R&D scientists in moving from projects and spreadsheets to a complete data management system that the entire team can use. The vendor claims that users can create innovative products using the latest predictive technology built on secure, cloud-based infrastructure. The Uncountable platform is an enterprise solution for experiment and lab management. R&D teams can manage all aspects of their lab from the Uncountable Platform, which includes LIMS and ELN functionality.

Proteins, which are remarkably complex machines, play a crucial role not only in the biological functions of your body but also in every living organism's processes. They serve as the fundamental units of life. As of now, there are approximately 100 million identified proteins, with discoveries being made regularly. Each protein possesses a distinctive three-dimensional shape that is essential to its functionality and purpose. However, determining a protein's precise structure is often a costly and lengthy endeavor, resulting in an understanding of only a small percentage of the proteins recognized by science. Addressing this growing disparity and developing methods to predict the structures of millions of yet-to-be-discovered proteins could significantly advance our ability to combat diseases, expedite the discovery of new treatments, and potentially unveil the secrets of life's mechanisms. The implications of such advancements could transform both medicine and our understanding of biology.

AIDDISON™ is an innovative drug discovery software that harnesses the capabilities of artificial intelligence (AI), machine learning (ML), and advanced 3D computer-aided drug design (CADD) techniques, serving as an essential resource for medicinal chemistry applications. This comprehensive platform streamlines both ligand-based and structure-based drug design, effectively merging all components necessary for virtual screening while also facilitating in-silico lead discovery and optimization processes. By leveraging these cutting-edge technologies, AIDDISON™ significantly enhances the efficiency and effectiveness of the drug development pipeline.

We combine clinical and experimental data through machine learning techniques to explore human disease biology and promote the development of precision medicine. Our innovative Contingent AI™ technology comprehends the intricate relationships present in the data, yielding advanced insights. To combat data bias, we refine our machine learning models based on decisions made during the pre-processing and feature engineering phases. We utilize zebrafish, cellular, and various phenotypic animal models to test and confirm in silico predictions through in vivo experiments, along with genetic modifications conducted both in vitro and in vivo to enhance translation. By employing active learning and computer vision on validated models that focus on cardiac, central nervous system, and rare disorders, we swiftly integrate new data into our machine learning frameworks, allowing for continuous improvement and adaptation in our methodologies. This iterative process not only enhances the accuracy of our predictions but also enables us to stay at the forefront of research in precision medicine.

Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.

Streamlined surveillance of diverse data sources, seamlessly integrated with a GVP IX compliant signal management platform, can revolutionize your safety data handling. The Evidex platform offers a ready-to-go, GVP-IX compliant signal management solution that simplifies your operations without the hassle of switching between various services. By modernizing your management processes, you can ensure they are audit-proof and efficient. This automation not only helps meet regulatory standards but also enhances the overall value generated for your organization. With automated signal detection, you can identify safety signals from established sources such as ICSR databases, the FDA's Adverse Event Reporting System (FAERS), VigiBase, and clinical trial data. Furthermore, you can incorporate additional data sources, including claims, electronic health records (EHR), and other unstructured information. By aggregating these diverse data pools, you can significantly improve signaling algorithms, streamline validations and assessments, and accelerate responses to pressing drug safety inquiries. Ultimately, this approach transforms how organizations manage and leverage safety data for better outcomes.